Table 1 Baseline characteristics and distribution of the sample population
Characteristics | Median (min., max.) | IQR (Q1, Q3) |
|---|---|---|
Age (years) | 60 (29, 75) | 52, 64 |
Follow-up* | 15.6 (1.5, 50.7) | (9.2, 22.5) |
Gender | Number of cases | Percentage (%) |
 Male | 40 | 70.2 |
 Female | 17 | 29.8 |
 Total | 57 | 100.0 |
Primary tumor | ||
 TX | 0 | 0 |
 T0 | 0 | 0 |
 Tis | 0 | 0 |
 T1 | 0 | 0 |
 T2 | 2 | 3.5 |
 T3 | 24 | 42.1 |
 T4 | 10 | 17.5 |
 Unknown | 21 | 36.8 |
Regional lymph nodes | ||
 NX | 1 | 1.7 |
 N0 | 6 | 10.5 |
 N1 | 15 | 26.3 |
 N2 | 12 | 21.0 |
 Unknown | 23 | 40.3 |
Metastasis | ||
 M0 | 1 | 1.7 |
 M1 | 9 | 15.8 |
 Unknown | 47 | 82.4 |
ECOG score | ||
 0 | 15 | 26.3 |
 1 | 9 | 15.8 |
 2 | 32 | 56.1 |
Clinical stage | ||
 cTNM frequency | 5 | 8.8 |
 pTNM frequency | 30 | 52.6 |
 Missing | 22 | 38.6 |
 Total | 57 | 100 |
Gene types | ||
 KRAS | 39 | – |
 NRAS | 29 | – |
 BRAF | 44 | – |
 EGFR | 35 | – |
RAS status | ||
 NRAS wild type | 24 | – |
 KRAS wild type | 19 | – |
 KRAS mutation | 20 | – |
 Undetected/unknown | 100 | – |
Location of primary lesion | ||
 Rectum | 17 | 29.8 |
 Sigmoid colon | 22 | 38.6 |
 Splenic flexure of colon | 2 | 3.5 |
 Ileocecal part | 1 | 1.7 |
 Rectum + sigmoid colon | 2 | 3.5 |
 Others | 11 | 19.3 |
 Missing | 2 | 3.5 |
 Total | 57 | 100 |
Location of tumor metastasis | ||
 Lung | 1 | 1.7 |
 Liver | 21 | 37.0 |
 Others | 2 | 3.5 |
 Lung + liver | 3 | 5.3 |
 Liver + others | 2 | 3.5 |
 Missing | 28 | 49.1 |
 Total | 57 | 100 |
Pre-regorafenib treatment line | ||
 1 | 13 | 22.8 |
 ≥ 2 | 37 | 64.9 |
 Missing | 7 | 12.3 |
 Total | 57 | 100 |
Previous treatment regimens | ||
 VEGFR & EGFR inhibitor | 8 | 14.3 |
 Anti-EGFR only | 13 | 23.2 |
 Only anti-VEGFR | 12 | 21.4 |
 #Others | 23 | 41.1 |
 Total | 56 | 100.0 |
Treatment prior to regorafenib | ||
 mFOLFOX6 | 13 | 22.8 |
 XELOX | 27 | 47.4 |
 FOLFIRI | 5 | 8.8 |
 XELIRI | 1 | 1.7 |
 FOLFOXIRI | 1 | 1.7 |
 Others | 10 | 17.5 |
 Total | 57 | 100 |
Initial dose of regorafenib in (mg) | ||
 40 | 1 | 1.8 |
 80 | 12 | 21.1 |
 120 | 2 | 3.5 |
 160 | 28 | 49.1 |
 Missing | 14 | 24.6 |
 Total | 57 | 100.0 |
Intrahepatic evaluation after 1st administration of HAIC + regorafenib | ||
 PR | 20 | 35.1 |
 SD | 20 | 35.1 |
 Missing | 17 | 29.8 |
 Total | 57 | 100.0 |
 ORR | (20/40) | 50.0 |
 DCR | (40/40) | 100.00 |
Extrahepatic evaluation after 1st administration of HAIC + regorafenib | ||
 PR | 4 | 7.0 |
 SD | 7 | 12.3 |
 PD | 7 | 12.3 |
 Other | 12 | 21.1 |
 Missing | 27 | 47.4 |
 Total | 57 | 100.0 |
 ORR | (4/30) | 13.3 |
 DCR | (11/30) | 36.7 |